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Association of reduced red blood cell deformability and diabetic
nephropathy
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Association of reduced red blood cell deformability and dia-
betic nephropathy.
Background. Impaired red blood cell deformability may play
a key role in the pathogenesis of chronic vascular complications
of diabetes mellitus and progression of renal failure. The present
study was conducted to test whether impaired red blood cell
deformability is indeed associated with development of diabetic
nephropathy.
Methods. We studied 57 adult type 2 diabetic patients divided
into three groups according to serum creatinine concentration.
Group I comprised 28 diabetic patients with normal renal func-
tion (serum creatinine concentration <1.5 mg/dL, mean 1.0 ±
0.3 mg/dL). Group II comprised 10 diabetic patients with re-
nal insufficiency (serum creatinine concentration ranging from
2 to 6 mg/dL, mean 3.9 ± 1.54 mg/dL). Group III consisted
of 19 diabetic subjects with end-stage renal disease (ESRD)
on hemodialysis (serum creatinine concentration ranging from
7.7 to 14.6 mg/dL, mean 10.1 ± 2.4 mg/dL). In addition, 11
(mean serum creatinine concentration 4.2 ± 1.5 mg/dL) and
10 (mean serum creatinine concentration 11.5 ± 3.6 mg/dL)
nondiabetic individuals, matched renal function for the diabetic
groups (group II and III, respectively) served as control. Red
blood cell deformability, measured by filtration technique, is
defined as the filtration rate of erythrocyte suspension through
a micropore filter divided by the filtration rate of a physiologic
buffer solution.
Results. In the diabetic cohort, we found substantially im-
paired red blood cell deformability in those with normal renal
function (group I). With further renal function loss, an increased
impairment in red blood cell deformability was observed. Dia-
betic patients with renal insufficiency (group II) when compared
to non-diabetic controls (renal insufficiency) had a significantly
greater impairment in red blood cell deformability (P = 0.01).
The nondiabetic cohort (renal insufficiency), on the other hand,
manifested significant impairment in red blood cell deformabil-
ity. Their degree of impairment was statistically higher than that
in diabetic patients with normal renal function (P = 0.0005).
Interestingly, there was a progressive increase in red blood cell
deformability impairment, along with progression of renal in-
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sufficiency, and thus no significant difference in the degree of
red blood cell deformability impairment was observed between
diabetic and nondiabetic patients with ESRD (P = 0.52). There
is significant correlation between serum creatinine and impair-
ment in red blood cell deformability in both diabetic (group II
plus III) (r = 0.43, P = 0.02) and nondiabetic (r = 0.62, P =
0.003) cohorts.
Conclusion. In diabetic patients, early impairment in red
blood cell deformability appears in patients with normal re-
nal function, and progressive impairment in red blood cell de-
formability is associated with renal function loss in all patients
regardless of the presence or absence of diabetes.
Diabetic nephropathy, a serious microvascular compli-
cations of diabetes mellitus, is the leading cause of end-
stage renal disease (ESRD) [1]. Hyperglycemia is the
main metabolic perturbation causing irreversible kidney
damage in diabetes [2, 3], but the mechanism by which
hyperglycemia results in nephropathy is not well defined.
Multiple glucose metabolites and reaction products ac-
cumulate as a consequence of hyperglycemia. The aldose
reductase pathway leading to toxic levels of sorbitol and
activation of isoform(s) of protein kinase C (PKC) [4] is
proposed to explain how hyperglycemia damages tissues
[3]. Accruing evidence supports a key role for advanced
glycation end-products (AGEs) formed by nonenzymatic
glycation and oxidation (glycoxidation) reactions in the
pathogenesis of diabetic nephropathy [5–8].
Impaired red blood cell deformability, is a hemorheo-
logic perturbation induced by diabetes and renal failure.
Its effect on the microcirculation have also been impli-
cated in the pathogenesis of diabetic vascular complica-
tions [9–11]. Recently, a number of studies have provided
evidence that impaired red blood cell deformability is
linked to AGEs accumulation. Nonenzymatic glycation
of several proteins, especially red cell-membrane glyco-
proteins and hemoglobin has been found in patients
with diabetes [12, 13], and such a biochemical modifi-
cation of the erythrocyte is one factor that may account
for altered rheologic properties of human erythrocytes
in diabetes [14]. This hypothesis was confirmed by our
recent demonstration that pimagedine, an agent known
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Table 1. Patient demographics and clinical features
Normal renal function Renal insufficiency End stage renal disease
(N = 28) (N = 21) (N = 29)
Group I Group II Control Group III Control
Diabetic (28) Diabetic (10) Non-Diabetic (11) Diabetic (19) Non-Diabetic (10)
Age 61.2 [8.6] 53.3 [10.8] 58.7 [14.0] 61.5 [9.6] 44.3 [11.6]
Gender male/female 9/19 7/3 8/3 8/11 5/5
Hemoglobin Ac % 8.6a [1.4] 7.6 [1.3] Not assessed 6.7 [1.5] Not assessed
Serum creatinine mg/dL 1.0 [0.3] 3.9 [1.5] 4.2 [1.5] 10.1 [2.4] 11.5 [3.6]
Mean corpuscular volume FL 87.6 [6.5] 88.4 [7.0] 84.0 [3.1] 87.7 [6.6] 86.1 [2.9]
Hematocrit % 39.6b [3.3] 36.1 [3.1] 34.2 [4.0] 34.6 [4.7] 34.3 [6.7]
Urea reduction ratio — — — 72.3 [6.5] 68.4 [11.8]
Mean [SD].
aP = 0.0005 significantly higher homoglobin Ac noted in diabetic patients with normal renal function compared to diabetic patients with end-stage renal disease.
bP = 0.0005 significantly higher mean hematocrit level observed in diabetic subjects with normal renal function compared to diabetic and non-diabetic patients with
renal insufficiency and end-stage renal disease.
to specifically block AGEs formation [15, 16], effectively
corrects impaired red blood cell deformability in an ani-
mal model of diabetes. Conversely, in this study, red blood
cell deformability deteriorated and returned to pretreat-
ment impairment by week 10 following pimagedine with-
drawal [17]. This finding was supported further by the
course of red blood cell deformability noted in diabetic
subjects with ESRD treated with pimagedine [18] and by
the significant and independent correlation of AGE car-
boxylmethyllysine (CML) with red blood cell deforma-
bility [abstract; Brown et al, Am Soc of Nephrol 14:609A,
2003]. The present study was designed to test the hypoth-
esis that impaired red blood cell deformability correlates
with development and progression of diabetic nephro-
pathy.
METHODS
Subjects
Fifty-seven diabetic patients, divided into three groups
according to serum creatinine concentration, participated
in this study. Eleven (renal insufficiency) and ten (ESRD)
nondiabetic patients served as controls. Group designa-
tion, patients’ demographics, and clinical features are
listed in Table 1.
Group I comprised 28 diabetic patients whose serum
creatinine was <1.5 mg/dL (mean 1.0 ± 0.3 mg/dL).
Group II comprised 10 diabetic patients with renal insuffi-
ciency whose serum creatinine ranged from 2 to 6 mg/dL
(mean 3.9 ± 1.5 mg/dL) and group III consisted of 19
diabetic patients with ESRD on hemodialysis, with a
serum creatinine ranging from 7.7 to 14.6 mg/dL (mean
10.1 ± 2.4 mg/dL). In the nondiabetic cohort, 11 patients
with renal insufficiency (mean serum creatinine of 4.2 ±
1.5 mg/dL) and 10 with ESRD (mean serum creatinine
11.5 ± 3.6 mg/dL) were controls for diabetic groups II
and III, respectively. In addition, there was no significant
group difference in mean plasma cholesterol concentra-
tions, approximately 5% of diabetic and nondiabetic pa-
tients actively smoked cigarettes, and three patients in
group I, two in group II, and two in group III had clini-
cal evidence of cardiovascular disease. No patients in the
nondiabetic group had clinically evident cardiovascular
disease.
Determination of erythrocytes deformability
Red blood cell deformability, measured by filtration
technique, is defined by the rate of filtration of a di-
lute (hematocrit of 4.0%) suspensions of washed ery-
throcytes in phosphate-buffered saline (PBS) solution
through polycarbonate membranes with straight chan-
nels of 3 l pore diameter (Nucleopore; Corning, Acton,
MA, USA) under a constant negative pressure (−20 cm
H2O), compared to the rate of filtration of an equal vol-
ume of buffer. This technique used in our laboratory is
a modification of the method of Reid et al [19], and has
been described previously [17, 20]. A major problem with
this method (especially those with pore diameters of 3
micron) is its relationship to mean cell volume (MCV)
[21], and a substantial occlusion of the pores and decre-
ment in flow rate due to the presence of hyperproteine-
mia and contaminating leukocytes [22, 23]. The technique
was designed to reduce confounding factors: (1) suspen-
sions of washed erythrocytes in PBS instead of whole
blood were used to eliminate hyperglycemia and hyper-
viscous plasma, (2) a polycarbonate membrane with pore
size of 3 l was chosen because it is to be more sensitive
to small changes in erythrocyte rheology than filtration
through a 5 l pore [24], (3) Imugard IG 500 cotton wool
(Terumo, Tokyo, Japan) prefiltration method was used to
reduce leukocyte contamination below the critical level
of <0.025 × 109/I [22] and to remove 99% of platelets
and various cell-protein interactions [25], (4) strict ad-
herence to buffer (PBS), pH 7.4, and osmolality (295 to
300 mmol/kg) was maintained to avoid the influence of
buffer on the MCV of red blood cells, and (5) pH and
osmolality remained constant from batch to batch [21].
This system used in our laboratory for nearly a decade
has a high degree of sensitivity in detecting abnormal red
blood cell deformability.
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Fig. 1. Red blood cell deformability abnor-
mality in diabetic and nondiabetic patients
with nephropathy. ∗P = 0.0005, significantly
greater impairment in red blood cell deforma-
bility noted in diabetic patients with nor-
mal renal function (group I) compared with
normal healthy controls. ∗∗P = 0.01, signif-
icantly impaired red blood cell deformabil-
ity in diabetic patients with renal insufficiency
(group II) compared to the nondiabetic con-
trol group. NS is no significant difference be-
tween diabetic and nondiabetic patients with
end-stage renal disease (ESRD) (group III vs.
control).
A pure suspension of washed erythrocytes was pre-
pared as follows: whole blood from heparinized venous
blood was filtered through Imugard IG 500 cotton wool
[22], the effluents were centrifuged at 12,500 rpm for
10 minutes; the plasma, buffy coat, and uppermost red
blood cell layer were removed. Packed red blood cells
were washed three times in PBS solution. Washed ery-
throcytes, aspirated from the middle of the packed ery-
throcyte column, were resuspended in isotonic PBS to a
final concentration of 4%. In each filtration experiment,
a paired test was included. The flow time required for
5 mL of buffer to pass through the filter was determined
as a blank value. The same measurement with the 4% red
cell suspensions was performed. A qualitative measure-
ment of red blood cell deformability was expressed as a
deformability index (DI) defined as the time required for
5 mL of red cell suspension to filter, divided by the time
required for an equal volume of buffer to filter. The DI is
reported as the average of two to three repeated tests. DI
was standardized to a normal reference mean obtained
from a group of age matched healthy adults (N = 30,
mean DI of healthy adults 4.33 ± 0.14, DI = 1.0).
To avoid any influence of MCV on red blood cell de-
formability results, MCV was measured for subjects in
each cohort, and there is no statistical significant differ-
ence in mean MCV values between diabetic and non-
diabetic patients in both renal insufficiency and ESRD
cohorts (Table 1). Although mean MCV in diabetic pa-
tients with renal insufficiency (group II) was 4 fl greater
than that of nondiabetic control subjects, red blood cell
filtration through a 3 l pore filter of the same lot and batch
(in the range of MCV measured in this study) will result
in small changes in red blood cell filtration that would not
significantly influence our results [26].
Statistical analysis
Statistical analysis was performed using the unpaired
two-tailed Student t test. Linear regression was used to
determine correlation between variables. Statistical sig-
nificance is indicated by P < 0.05. Data are expressed as
mean ± standard deviation (SD).
RESULTS
As shown in Figure 1, in the diabetic group, a substan-
tially greater impairment in red blood cell deformability
was noted early in patients with normal renal function
(group I) (compared with normal healthy control, P =
0.0005). Subsequently, an increased impaired red blood
cell deformability was found with further renal function
loss, especially in diabetic patients with renal insufficiency
(group II) when compared with nondiabetic subjects with
matched renal insufficiency (P = 0.01). In the nondiabetic
cohort marked impaired red blood cell deformability was
also noted in patients with renal insufficiency, their degree
of impairment was statistically much higher than in dia-
betic patients with normal renal function (P = 0.0005).
In advanced renal failure there was no significant dif-
ference between diabetic and nondiabetic patients with
ESRD (P = 0.52). A strong and significant correlation
between serum creatinine concentration and red blood
cell deformability was evident in both diabetic (groups II
and III) (r = 0.43, P = 0.02) and nondiabetic (r = 0.62,
P = 0.003) patient controls (Fig. 2).
DISCUSSION
Red blood cell deformability, generally accepted as the
passive change in the shape of red blood cells in response
to shear forces, is a pivotal determinant of blood flow and
function in the microcirculation [9]. Several hypotheses to
explain impaired red blood cell deformability proposed
include elevated blood glucose concentration and hyper-
osmolarity [9]; hypoinsulinemia [27]; alterations in red
blood cell membrane lipid composition [28]; increased
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Fig. 2. Correlation between red blood cell deformability and serum
creatinine in diabetic and nondiabetic patients with nephropathy. A
significant correlation between serum creatinine concentration and im-
paired red blood cell deformability were observed in both diabetic (r =
0.43, P = 0.02) and nondiabetic (r = 0.62, P = 0.003) patient groups.
internal viscosity [10]; accumulation of sorbitol via en-
hanced activity of the polyol pathway [29]; and increased
erythrocyte membrane rigidity caused by glycation of ery-
throcyte membrane [14]. The primary mechanism under-
lying reduced red blood cell deformability observed in
diabetes and in renal failure remains unknown.
Several lines of evidence suggest that excessive accu-
mulation of AGEs may play a critical role in the alteration
of rheologic properties of red blood cell deformability
in those patients with diabetes (with or without renal
disease) and in nondiabetic patients with renal disease
[12, 14, 17, 18]. Supporting evidence for this thesis in-
clude the following. First, chronic hyperglycemia makes
the relative long half-life of erythrocytes a prime tar-
get for AGEs formation, for example, major membrane
protein and hemoglobin are glycated [12, 13]. Second,
the influence on red blood cell deformability by pim-
agedine, a potent AGE blocker, has been noted in both
a rabbit model of hyperglycemia [17] and in diabetic
patients with ESRD [18]. Impaired red blood cell de-
formability was restored to normal after treatment (over
months) with the pimagedine. Furthermore, red blood
cell deformability impairment returned to baseline val-
ues in the diabetic animals and subjects after pimage-
dine was discontinued. Finally, in another study [abstract;
Brown et al, Am Soc of Nephrol 14:609A, 2003] plasma
AGE (CML) strongly and significantly correlated with
red blood cell deformability (r = 0.82, P = 0.0005) in
diabetic and nondiabetic patients with renal disease. In
that study, application of multiple regression analysis and
controlling for serum creatinine, plasma CML concentra-
tion remained a significant independent correlate of red
blood cell deformability.
Taken together, these studies suggest that AGE does
not correlate with red blood cell deformability through
serum creatinine, conversely, they suggest that AGE is
independently associated with impaired red blood cell
deformability.
It is important to note that in the rabbit and human
studies, the pimagedine-mediated improvement in red
blood cell deformability occurred despite persistence in
elevation of blood glucose and hemoglobin A1c (HbA1c).
These findings suggest that hyperglycemia and HbA1c,
per se, may have little importance in directly influenc-
ing red blood cell deformability. An association between
AGEs and progression of renal disease is afforded by the
report that tissue and serum AGEs levels rise as renal
function declines in diabetic patients with nephropathy
[7]. In the present study, early impaired red blood cell
deformability was noted in diabetic patients with normal
renal function (Fig. 1) and a strong correlation between
serum creatinine and red blood cell deformability impair-
ment was observed in the diabetic cohorts (groups II and
III) (r = 0.43, P = 0.02). These observations prompt the
hypothesis that impairment in red blood cell deformabil-
ity observed in diabetic patients (with or without renal
failure), may be induced by excessive accumulation of
AGEs and/or AGE mediated action such as oxidative
stress. Although not measuring serum AGEs directly is a
weakness of our study, we do not think that this detracts
from our finding of a strong and significant relationship
between red blood cell deformability and renal function.
We showed that in a diabetic cohort early impairment
in red blood cell deformability appears in patients with
normal renal function, and a persistently increased im-
pairment in red blood cell deformability is associated
with renal function loss. Additionally, more impairment
in red blood cell deformability was observed in dia-
betic patients with renal insufficiency, compared with
matched renal function of nondiabetic subjects with re-
nal insufficiency (P = 0.01) (Fig. 1). These findings mean
that hyperglycemia and impaired renal function could be
pathogenic factors that are important for both the de-
velopment of impairment in red blood cell deformability
and accumulation of AGEs.
As shown in Figure 1, an appreciable impairment in
red blood cell deformability was also noted in the nondia-
betic patients with renal insufficiency. Furthermore, their
degree of impairment was much more severe, when com-
pared to diabetic patients with normal renal function (P =
0.0005). There was a strong and significant correlation be-
tween serum creatinine concentration and impairment of
red blood cell deformability (r = 0.62, P = 0.003) in the
nondiabetic cohort as well (Fig. 2). The clinical signifi-
cance of these findings has not yet been defined. Whether
or not impaired red blood cell deformability as seen in
nondiabetic controls also contributes to development of
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uremia or extrarenal comorbidity is unknown. While any
difference in AGEs accumulation between diabetic and
nondiabetic ESRD patients must be determined, some
difference in red blood cell deformability impairment be-
tween diabetic and nondiabetic patient cohorts is noted
by comparing areas under the bars in Figure 1. In dia-
betic patients, red blood cell deformability is profoundly
altered early, prior to the onset of renal insufficiency and
ESRD. By contrast, the impairment in red blood cell de-
formability is initially observed in nondiabetic patients
with the onset of renal insufficiency. Red blood cell de-
formability impairment in nondiabetic patients reaches
a maximum once ESRD develops. Apparently, impaired
red blood cell deformability observed in the nondiabetic
cohort seems to be influenced by renal functional impair-
ment alone.
The role of impaired renal function in the formation
of AGEs has been investigated. It was demonstrated that
nonenzymatic modifications in uremia are not only re-
lated to carbohydrate-derived adducts generated by the
Maillard reaction, such as AGE-peptides [7, 30], pento-
sidine [31], and CML [32], but may also be stimulated
by carbonyl intermediates resulting from the oxidation
of glucose, ascorbic acid, and lipid peroxidation [33, 34].
As shown in Figure 1, impairment in red blood cell de-
formability was much less in nondiabetic patients with
renal insufficiency compared with diabetic subjects with
a similar degree of renal impairment (P = 0.01), but
there is no significant difference in the degree of red
blood cell deformability impairment between diabetic
and nondiabetic patients once ESRD develops (P=0.52).
Miyata et al [34] measured CML, pentosidine, and mal-
ondialdehyde (MDA)-lysine levels in diabetic and non-
diabetic hemodialysis patients and found no significant
difference in the levels of all three AGEs. This observa-
tion suggests that impaired red blood cell deformability
observed in nondiabetic cohort patients may be associ-
ated with the accumulation of AGEs and may explain
why we noted no significant difference in the degree of
impairment in red blood cell deformability between di-
abetic and nondiabetic patients once ESRD was mani-
fested. Although one report at variance with this line of
thinking showed greater elevation of AGE peptide levels
(low-molecular-weight) in diabetic patients compared to
nondiabetic hemodialysis patients [35].
Whether impaired red blood cell deformability results
from renal function decline, and therefore serves as a
marker for nephropathy, or is a major factor directly con-
tributing to nephropathy in diabetic and nondiabetic pa-
tients are issues that are now under study.
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